A share price of Aurinia Pharmaceuticals Inc [AUPH] is currently trading at $11.45, up 9.15%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AUPH shares have gain 28.80% over the last week, with a monthly amount glided 50.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer downgraded its rating to Perform on November 04, 2022. Oppenheimer upgraded its rating to a Outperform and decreased its price target to $31 on December 10, 2021. Oppenheimer downgraded its rating to a Perform but $32 remained the price target by the analyst firm on October 28, 2021. H.C. Wainwright reiterated a Buy rating for this stock on January 25, 2021, and upped its price target to $35. In a note dated November 03, 2020, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $34 to $28.
Aurinia Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $5.20 and $10.67. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $11.45 at the most recent close of the market. An investor can expect a potential drop of -6.11% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Trailing Twelve Months sales for Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] were 260.11M which represents 22.41% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] is 5.23. Also, the Quick Ratio is 4.63, while the Cash Ratio stands at 0.68. Considering the valuation of this stock, the price to sales ratio is 5.79, the price to book ratio is 4.53 and price to earnings (TTM) ratio is 26.78.
Transactions by insiders
Recent insider trading involved Keenan Greg, Chief Medical Officer, that happened on Mar 07 ’25 when 8305.0 shares were sold. Chief Executive Officer, Greenleaf Peter completed a deal on Mar 03 ’25 to sell 0.2 million shares. Meanwhile, Chief Executive Officer Greenleaf Peter sold 0.16 million shares on Mar 04 ’25.
